How the Top 300 was constructed
There is no single official 300-company revenue table covering the EU, Switzerland, the United Kingdom and Israel. The atlas therefore uses a transparent composite approach.
| Range | Tier | Basis | Interpretation |
|---|---|---|---|
| 1–100 | Regional leaders | Major manufacturers, biopharma, generics and CDMOs | FUZKK atlas priority, not a single official ranking. |
| 101–300 | Extended manufacturing selection | Companies from industry associations, public manufacturer registries and national ecosystems | Extends geography and specialist manufacturing profiles. |
| All positions | FUZKK fit | Product/API, Lumex, LabEx and Medical Devices | Shows potential applicability rather than actual deployment. |
Public sources
- EFPIA — leading research-based companies and national associations
- Medicines for Europe — generics, biosimilars and value-added medicines
- EUCOPE — small and mid-sized innovative companies
- EMA EudraGMDP — manufacturing/import authorisations and GMP
- ABPI — UK pharmaceutical-industry companies
- MHRA — UK medicines regulator
- Interpharma — research-based companies in Switzerland
- Swissmedic — establishment licence holders
- Pharma Israel and the Israeli Ministry of Health
- Israeli Drug Registry
What the atlas does not claim
- that positions 1–300 form a single official revenue table;
- that every site was individually rechecked in a GMP registry on the build date;
- that a specific equipment model is installed at a site;
- that a company uses FUZKK;
- that the proposed utility set is already validated for a particular site.